La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Arch Biopartners Croissance future

Future contrôle des critères 1/6

Arch Biopartners devrait augmenter son chiffre d'affaires de 15.6% par an. Le BPA devrait augmenter de diminuer de 35.3% par an.

Informations clés

n/a

Taux de croissance des bénéfices

-35.3%

Taux de croissance du BPA

Life Sciences croissance des bénéfices	17.8%
Taux de croissance des recettes	15.6%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	09 Apr 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

OTCPK:ACHF.F - Estimations futures des analystes et données financières antérieures (CAD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2025	2	N/A	N/A	N/A	1
9/30/2024	2	N/A	N/A	N/A	1
3/31/2024	2	-2	0	0	N/A
12/31/2023	2	-2	0	0	N/A
9/30/2023	2	-3	0	0	N/A
6/30/2023	2	-4	2	2	N/A
3/31/2023	2	-3	1	1	N/A
12/31/2022	1	-3	-1	-1	N/A
9/30/2022	1	-1	0	0	N/A
6/30/2022	3	0	0	0	N/A
3/31/2022	5	0	-4	-4	N/A
12/31/2021	4	0	-1	-1	N/A
9/30/2021	4	-1	-3	-3	N/A
6/30/2021	2	-3	-4	-4	N/A
3/31/2021	0	-7	-2	-2	N/A
12/31/2020	0	-6	-2	-2	N/A
9/30/2020	0	-5	-2	-2	N/A
6/30/2020	0	-4	-2	-2	N/A
3/31/2020	0	-2	-2	-2	N/A
12/31/2019	0	-2	-2	-2	N/A
9/30/2019	0	-2	-2	-2	N/A
6/30/2019	0	-2	-2	-2	N/A
3/31/2019	N/A	-3	-2	-2	N/A
12/31/2018	N/A	-3	-2	-2	N/A
9/30/2018	N/A	-3	-2	-2	N/A
6/30/2018	N/A	-3	-2	-2	N/A
3/31/2018	N/A	-2	-1	-1	N/A
12/31/2017	N/A	-2	N/A	-1	N/A
9/30/2017	N/A	-2	N/A	-1	N/A
6/30/2017	N/A	-2	N/A	-1	N/A
3/31/2017	N/A	-1	N/A	-1	N/A
12/31/2016	N/A	-1	N/A	-1	N/A
9/30/2016	N/A	-1	N/A	-1	N/A
6/30/2016	0	-1	N/A	-1	N/A
3/31/2016	0	-1	N/A	-1	N/A
12/31/2015	0	-1	N/A	-1	N/A
9/30/2015	0	-1	N/A	0	N/A
6/30/2015	0	-1	N/A	-1	N/A
3/31/2015	0	-1	N/A	0	N/A
12/31/2014	0	-1	N/A	0	N/A
9/30/2014	0	0	N/A	0	N/A
6/30/2014	0	0	N/A	0	N/A
3/31/2014	0	0	N/A	0	N/A
12/31/2013	0	0	N/A	0	N/A
9/30/2013	0	0	N/A	0	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de ACHF.F est supérieure au taux d'épargne ( 2.5% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de ACHF.F devraient croître plus rapidement que le marché US

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de ACHF.F devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ACHF.F ( 15.6% par an) devrait croître plus rapidement que le marché US ( 8.8% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ACHF.F ( 15.6% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ACHF.F devrait être élevé dans 3 ans

Arch Biopartners Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Arch Biopartners Inc. Announces its Cilastatin Drug Candidate to Participate in Pontiac Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

Arch Biopartners Inc. announced that it has received CAD 0.6 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.6 million in funding

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

Arch Biopartners Inc. Announces St. Michael's Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Anesthesia Clinical Trials Unit Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for Lsalt Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with Sars-Cov-2

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated-Acute Kidney Injury

Arch Biopartners Receives Permission from U.S. FDA to Proceed with Phase II Acute Kidney Injury Trial

Arch Biopartners Inc., Annual General Meeting, Apr 02, 2024

Arch Biopartners Inc. Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Arch Biopartners Inc. Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Arch Biopartners Inc., Annual General Meeting, Mar 30, 2023

Arch Biopartners Inc Appoints David Luke as Strategic Advisor for the Clinical Trial Development of the Company's Drug Candidate

Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

Arch Biopartners' Lead Drug Lsalt Peptide to Enter the Canadian Treatments for Covid-19 (Catco) Trial

Arch Biopartners Inc. Provides Update on Phase II Trial for LSALT Peptide

Arch Biopartners Inc. Files New Patent Application for Novel Antibody Candidates Targeting DPEP-1 Mediated Organ Inflammation

Arch Biopartners Inc. Completes Enrollment in Phase II Trial of Metablok (LSALT Peptide) in Hospitalized Patients with COVID-19

Arch Biopartners Receives Health Canada Authorization to Amend Phase II Trial Protocol for LSALT Peptide

Arch Biopartners Inc. Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients

Arch Biopartners Inc. Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase Ii Trial for Lsalt Peptide

University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients with Arch Biopartners Inc

Arch Biopartners Inc. announced that it has received CAD 0.645 million in funding

Arch Biopartners Inc. announced that it expects to receive CAD 0.645 million in funding

Arch Biopartners Inc, Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19

Arch Biopartners Inc. Announces First Patient Dose in Phase II Trial to Treat Complications in COVID-19

Arch Biopartners Inc. Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance